Oncopeptides AB (ONCO): key financial figures for fiscal year 2025 (in SEK), standardized from XBRL/iXBRL filings by Hub-Equity:
- Revenue (FY2025)
- kr 71.1M
- Net Income/Loss (FY2025)
- -kr 249.6M
- Total Assets (FY2025)
- kr 135.4M
- Total Equity (FY2025)
- -kr 58.9M
- Cash Flows from Operating Activities (FY2025)
- -kr 222.9M
Source: Oncopeptides AB annual_report filing (FY2025). Full income statement, balance sheet and cash flow, restatement-aware and traceable to the source filing, at Hub-Equity.
